Overcoming Resistance to Targeted Therapies in Cancer

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


The recent discovery of oncogenic drivers and subsequent development of novel targeted strategies has significantly added to the therapeutic armamentarium of anti-cancer therapies. Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma. However, although initial therapeutic responses to targeted therapies can be substantial, many patients will develop disease progression within 6-12 months. An increasing application of powerful omics-based approaches and improving preclinical models have enabled the rapid identification of secondary resistance mechanisms. Herein, we discuss how this knowledge has translated into rational, novel treatment strategies for relapsed patients in genomically selected cancer populations.
Original languageEnglish
Pages (from-to)896-908
Number of pages13
JournalSeminars in Oncology
Issue number6
Early online date25 Sep 2015
Publication statusPublished - Dec 2015


Dive into the research topics of 'Overcoming Resistance to Targeted Therapies in Cancer'. Together they form a unique fingerprint.

Cite this